| REVIEW ARTICLE |
|
| Year : 2023 | Volume
: 26
| Issue : 2 | Page : 122-133 |
|
|
The influence of calcium silicate-based cement on osseous healing: A systematic review and meta-analysis
Ruchika Roongta Nawal1, Sudha Yadav1, Sangeeta Talwar1, Rajeev Kumar Malhotra2, Preeti Jain Pruthi1, Shruti Goel1, Reema Malik1, Mayank Shailat1
1 Department of Conservative Dentistry and Endodontics, Maulana Azad Institute of Dental Sciences, New Delhi, India
2 Delhi Cancer Registry, Dr BRA IRCH, All India Institute of Dental Sciences, New Delhi, India
Correspondence Address:
Dr. Sudha Yadav
Department of Conservative Dentistry and Endodontics, Maulana Azad Institute of Dental Sciences, New Delhi - 110 002
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jcd.jcd_498_22
|
|
|
Objectives: The purpose of this systematic review was to analyze the effect of commercially available calcium silicate-based bioactive endodontic cement (BEC) on treatment outcome when used as root repair material in human permanent teeth and to compare it with traditional materials.
Methods: PubMed, Embase, and Cochrane Library were searched until June 2020. Randomized clinical studies and observational studies with a minimum 1-year follow-up and sample size of at least 20 were included. Risk of bias (ROB) was assessed using Cochrane's ROB tool and the National Institutes of Health Quality Assessment Tool.
Results: Thirty-nine studies were included in the systematic review. Majority of the studies used mineral trioxide aggregate. The pooled success rate for BEC was estimated by a random-effects method as 90.49% (95% confidence interval [CI]: 88.4992.34, I2 = 54%). Eleven studies comparing BEC with traditional materials were included in the meta-analysis. The use of BEC significantly improved the treatment outcome when compared to traditional materials with odds ratio (OR) = 2.15 (95% CI: 1.57–2.96, I2 = 0.8%, P = 0.433).
Conclusion: Very low-to-moderate-quality evidence suggests that the use of BEC as root repair material enhanced the treatment outcome. High-quality studies are required for the newer BEC to establish their clinical performance. Registration: PROSPERO CRD42020211502.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
